DOCSLIB.ORG

Dexketoprofen for Pain (Keral)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dexketoprofen for Pain (Keral) Page 1 of 4 View this article online at: patient.info/medicine/dexketoprofen-for-pain-keral Dexketoprofen for pain (Keral) Dexketoprofen is a painkiller. It belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs). The usual dose is either half a 25 mg tablet every 4-6 hours, or one 25 mg tablet every 8 hours. Your doctor will tell you which dose is right for you. Pain relief is more rapid if dexketoprofen is taken when your stomach is empty - this means taking the tablets about 30 minutes before food. About dexketoprofen Type of medicine Non-steroidal anti-inflammatory drug (NSAID) Used for Short-term painful conditions Also called Keral® Available as Tablets Dexketoprofen is used to treat short-term painful conditions such as muscular sprains and strains, period (menstrual) pain, and toothache. It works by blocking the effect of chemicals called cyclo-oxygenase (COX) enzymes. These enzymes help to make other chemicals in the body, called prostaglandins. Some prostaglandins are produced at sites of injury or damage, and cause pain and inflammation. By blocking the effect of COX enzymes, fewer prostaglandins are produced, which means the pain is eased. Medicines like dexketoprofen are sometimes called non-steroidal anti-inflammatory drugs (NSAIDs). Before taking dexketoprofen Some medicines are not suitable for people with certain conditions, and sometimes a medicine may only be used if extra care is taken. For these reasons, before you start taking dexketoprofen, it is important that your doctor knows: If you have asthma or any other allergic disorder. If you have a stomach or duodenal ulcer, or if you have an inflammatory bowel disorder such as Crohn's disease or ulcerative colitis. If you are pregnant, trying for a baby, or breast-feeding. If you are under 18 or over 65 years of age. If you have liver or kidney problems. If you have a heart condition, or a problem with your blood vessels or circulation. If you have high blood pressure. If you have ever had blood clotting problems. Page 2 of 4 If you have a connective-tissue disorder, such as systemic lupus erythematosus (an inflammatory condition also called lupus, or SLE). If you are taking any other medicines. This includes any medicines you are taking which are available to buy without a prescription, such as herbal and complementary medicines. If you have ever had an allergic reaction to any other NSAID (such as aspirin, ibuprofen, diclofenac, or indometacin), or to any other medicine. How to take dexketoprofen Before you start taking dexketoprofen, read the manufacturer's printed information leaflet from inside the pack. The manufacturer's leaflet will give you more information about the tablets and provide a full list of the side-effects which you may experience from taking them. Your doctor will tell you how many tablets to take and how often to take them, but this will be no more three 25 mg tablets in total each day. Depending upon your condition, you will be asked to take either half a tablet every 4-6 hours, or one tablet every 8 hours. Take the tablets with a drink of water. They work more quickly if you take them when your stomach is empty, so ideally they should be taken about 30 minutes before food. However, if taking the tablets makes you feel queasy, then you will be better taking your doses after food as this will help to reduce any feelings of sickness. If you forget to take a dose, take it as soon as you remember unless your next dose is due. If your next dose is due, then take the dose which is due but leave out the forgotten one. Do not take two doses together to make up for a missed dose. Getting the most from your treatment Your doctor will prescribe you the lowest effective dose of dexketoprofen for the shortest time. This is to reduce the risk of side-effects. Take the tablets exactly as your doctor tells you to. Try to keep any follow-up appointments with your doctor. This is so your doctor can check on your progress. If you have asthma, symptoms such as wheeze or breathlessness can be made worse by dexketoprofen. If this happens to you, you should stop taking the tablets and see your doctor as soon as possible. If you buy any medicines, check with a pharmacist that they are safe to take with dexketoprofen. If you are having an operation or dental treatment, tell the person carrying out the treatment which medicines you are taking. Can dexketoprofen cause problems? Along with their useful effects, most medicines can cause unwanted side-effects although not everyone experiences them. The table below contains some of the most common ones associated with dexketoprofen. You will find a full list in the manufacturer's information leaflet supplied with your medicine. The unwanted effects often improve as your body adjusts to the new medicine, but speak with your doctor or pharmacist if any of the following continue or become troublesome. Common dexketoprofen side-effects - these affect less than 1 in 10 people who take this medicine What can I do if I experience this? Indigestion, heartburn, abdominal discomfort If the discomfort continues, speak with your doctor Feeling or being sick, diarrhoea Drink plenty of liquid to replace any lost fluids. Try taking the tablets after meals Other less common side-effects: constipation, anxiety, headache, If any become troublesome, speak with your doctor feeling dizzy or tired Important: if you experience any of the following rare but possibly serious symptoms, stop taking dexketoprofen and contact your doctor for advice straightaway: If you have any breathing difficulties such as wheeze or breathlessness. Page 3 of 4 If you have any signs of an allergic reaction such as swelling around your mouth or face, or an itchy skin rash. If you pass blood or black stools, vomit blood, or have abdominal pains. If you experience any other symptoms which you think may be due to this medicine, speak with your doctor or pharmacist. How to store dexketoprofen Keep all medicines out of the reach and sight of children. Store in a cool, dry place, away from direct heat and light. Important information about all medicines Never take more than the prescribed dose. If you suspect that you or someone else might have taken an overdose of this medicine, go to the accident and emergency department of your local hospital. Take the container with you, even if it is empty. This medicine is for you. Never give it to other people even if their condition appears to be the same as yours. Do not keep out-of-date or unwanted medicines. Take them to your local pharmacy which will dispose of them for you. If you have any questions about this medicine ask your pharmacist. Further reading & references Manufacturer’s PIL, Keral® 25 mg tablets; A. Menarini Farmaceutica Internazionale SRL, The electronic Medicines Compendium. Dated October 2012. British National Formulary; 66th Edition (September 2013) British Medical Association and Royal Pharmaceutical Society of Great Britain, London Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions. Original Author: Current Version: Peer Reviewer: Helen Allen Helen Allen Dr John Cox Document ID: Last Checked: Next Review: 3689 (v24) 19/12/2013 18/12/2016 View this article online at: patient.info/medicine/dexketoprofen-for-pain-keral Discuss Dexketoprofen for pain (Keral) and find more trusted resources at Patient. Page 4 of 4 © EMIS Group plc - all rights reserved..
Load more

Recommended publications
  • Development and Validation of an Ultra Performance Liquid
    DOI: 10.4274/tjps.76588 Turk J Pharm Sci 2017;14(1):1-8 ORIGINAL ARTICLE Development and Validation of an Ultra Performance Liquid Chromatography Method for the Determination of Dexketoprofen Trometamol, Salicylic Acid and Diclofenac Sodium Deksketoprofen Trometamol, Salisilik Asit ve Diklofenak Sodyum Etkin Maddeleri için Ultra Performanslı Sıvı Kromatografisi Yönteminin Geliştirilmesi ve Validasyonu Sibel İLBASMIŞ TAMER Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey ABSTRACT Objectives: A simple, fast, accurate and precise method has been developed for the determination of dexketoprofen trometamol (DKP), salicylic acid (SA) and diclofenac sodium (DIC) in the drug solutions using ultra high performance liquid chromatography (UPLC). Materials and Methods: UPLC method is highly reliable and sensitive method to quantify the amount of the active ingredient and the method is validated according to ICH guidelines. Results: The developed method is found to be precise, accurate, specific and selective. The method was also found to be linear and reproducible. The value of limit of dedection (LOD) of DKP, SA, DIC were found 0.00325 µg/mL, 0.0027 µg/mL and 0.0304 µg/mL, respectively. The limit of quantitation (LOQ) of DKP, SA and DIC were found 0.00985 µg/mL, 0.0081 µg/mL and 0.0920 µg/mL, respectively. Conclusion: Proposed methods can be successfully applicable to the pharmaceutical preparation containing the above mentioned drugs (dexketoprofen trometamol, salicylic acid and diclofenac sodium). Even very small amounts of active substance can be analyzed and validations can be performed easily. Key words: Dexketoprofen trometamol, salicylic acid, diclofenac sodium, UPLC, validation ÖZ Amaç: Deksketoprofen trometamol (DKP), salisilik asit (SA) ve diklofenak sodyumun (DIC) ilaç çözeltisindeki analizi için ultra yüksek basınçlı sıvı kromatografisi (UPLC) kullanılarak basit, hızlı, doğru ve kesin bir yöntem geliştirilmiştir.
    [Show full text]
  • Ataxia Caused by a Single Dose of Dexketoprofen Trometamol
    Acta Biomed 2014; Vol. 85, N. 3: 269-270 © Mattioli 1885 Case report Ataxia caused by a single dose of dexketoprofen trometamol Sema Avcı, Selim Genç, Macit Aydın, Fatih Büyükcam, Seda Özkan Department of Emergency Medicine, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey Summary. Mushroom poisoning is an important reason of plant toxicity. Wild mushrooms that gathered from pastures and forests can be dangerous for human health. The clinical outcomes and symptoms of mushroom toxicity vary from mild gastrointestinal symptoms to acute multiple organ failure. Toxic effects to kidney and liver of amatoxin are common but cardiotoxic effects are unusual. In this case, we reported the cardiotoxic effect of amatoxin with the elevated troponin-I without any additional finding in electrocardiography, echo- cardiography and angiography Key words: cardiac enzyme, mushroom, poisoning, toxicity, troponin Introduction ture: 37.1ºC, hearth rate:75 beats/min. On physical examination, the patient was oriented, alert and con- Dexketoprofen trometamol is one of the non- scious. Neurological examination was normal except steroid anti-inflamatory drugs (NSAID) used as an- ataxia and dysarthria. She has no previous chronic dis- algesic (1). It is a water-soluable molecule and it is an eases. Laboratory results were as follows; glucose:102 active enantiomer of racemic ketoprofen (1). Peroral mg/dL, creatinine:0.61 mg/dl, alanine aminotransfer- dexketoprofen has considerable analgesic potency and ase (ALT): 8 U/L , aspartate aminotransferase (AST): well-tolerated adverse effects in patients who suffer 12 U/L, calcium:9.7 mg/dL, sodium:143 mEq/L, from acute and chronic pain (1).
    [Show full text]
  • A Combined Crystallographic and Computational Study on Dexketoprofen Trometamol Dihydrate Salt
    crystals Article A Combined Crystallographic and Computational Study on Dexketoprofen Trometamol Dihydrate Salt Patrizia Rossi 1 , Paola Paoli 1,* , Stella Milazzo 1, Laura Chelazzi 2 , Maria Paola Giovannoni 3, Gabriella Guerrini 3 , Andrea Ienco 4,* , Maurizio Valleri 5 and Luca Conti 6 1 Department of Industrial Engineering, University of Florence, via Santa Marta 3, 50139 Florence, Italy; p.rossi@unifi.it (P.R.); stella.milazzo@unifi.it (S.M.) 2 Centro di Cristallografia Strutturale, University of Florence, via della Lastruccia 3, Sesto F.no, 50019 Florence, Italy; laura.chelazzi@unifi.it 3 NEUROFARBA, Sezione Farmaceutica e Nutraceutica, University of Florence, Via Ugo Schiff 6, Sesto F.no, 50019 Florence, Italy; mariapaola.giovannoni@unifi.it (M.P.G.); gabriella.guerrini@unifi.it (G.G.) 4 CNR-ICCOM, via Madonna del Piano 10, Sesto F.no, 50019 Florence, Italy 5 A. Menarini Manufacturing Logistics and Services s.r.l., via R. Pilo 4, 50131 Florence, Italy; [email protected] 6 Department of Chemistry “U. Schiff”, University of Florence, via della Lastruccia 3, Sesto F.no, 50019 Florence, Italy; luca.conti@unifi.it * Correspondence: paola.paoli@unifi.it (P.P.); [email protected] (A.I.) Received: 29 June 2020; Accepted: 30 July 2020; Published: 31 July 2020 Abstract: Dexketoprofen trometamol is the tromethamine salt of dexketoprofen [(2S)-2-(3-benzoylphenyl) propanoic acid-2-amino-2-(hydroxymethyl)propane-1,3-diol], a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of moderate- to strong-intensity acute pain. The crystal structure of the hitherto sole known hydrate phase of dexketoprofen trometamol (DK-T_2H2O), as determined by single-crystal X-ray diffraction, is presented.
    [Show full text]
  • Package Leaflet: Information for the Patient Dexketoprofen Rowex 25 Mg Film-Coated Tablets Dexketoprofen
    Package leaflet: Information for the patient Dexketoprofen Rowex 25 mg Film-coated tablets Dexketoprofen Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dexketoprofen Rowex is and what it is used for 2. What you need to know before you take Dexketoprofen Rowex 3. How to take Dexketoprofen Rowex 4. Possible side effects 5. How to store Dexketoprofen Rowex 6. Contents of the pack and other information 1. What Dexketoprofen Rowex is and what it is used for Dexketoprofen Rowex is a pain killer from the group of medicines called non-steroidal anti- inflammatory drugs (NSAIDs). It is used to treat mild to moderate pain, such as muscular pain, painful periods (dysmenorrhoea), toothache. 2. What you need to know before you take Dexketoprofen Rowex Do not take Dexketoprofen Rowex if you are allergic to dexketoprofen or any of the other ingredients of this medicine (listed in section 6). are allergic to acetylsalicylic acid or to other non-steroidal anti-inflammatory medicines. have asthma or have suffered attacks of asthma, acute allergic rhinitis (a short period of inflamed lining of the nose), nasal polyps (lumps within the nose due to allergy), urticaria (skin rash), angioedema (swollen face, eyes, lips, or tongue, or respiratory distress) or wheezing in the chest after taking acetylsalicylic acid or other non-steroidal anti-inflammatory medicines.
    [Show full text]
  • 50 Mg/2Ml Solution for Injection/Infusion
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Product name> 50 mg/2ml solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains dexketoprofen trometamol corresponding to 25 mg of dexketoprofen. One ampoule (2 ml) contains dexketoprofen trometamol corresponding to 50 mg of dexketoprofen. Excipients with known effect: 200 mg ethanol (96 %) and 8.0 mg sodium chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion. Clear colourless solution, free from visible particles. pH 7.0-8.0 Osmolarity 270-328 mOsmol/l 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Symptomatic treatment of acute pain of moderate to severe intensity, when oral administration is not appropriate such as post-operative pain, renal colic and low back pain. 4.2 Posology and method of administration Posology Adults The recommended dose is 50 mg every 8 – 12 hours. If necessary, the administration can be repeated 6 hours apart. The total daily dose should not exceed 150 mg. <Product name> is intended for short term use and the treatment must be limited to the acute symptomatic period (no more than two days). Patients should be switched to an oral analgesic treatment when possible. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). In case of moderate to severe postoperative pain, <Product name> can be used in combination with opioid analgesics, if indicated, at the same recommended doses in adults (see section 5.1). Pediatric population <Product name> has not been studied in children and adolescents.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Nonsteroidal Anti-Inflammatory Drugs for Dysmenorrhoea (Review)
    Cochrane Database of Systematic Reviews Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD001751. DOI: 10.1002/14651858.CD001751.pub3. www.cochranelibrary.com Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 5 OBJECTIVES ..................................... 6 METHODS ...................................... 6 Figure1. ..................................... 8 Figure2. ..................................... 10 Figure3. ..................................... 12 RESULTS....................................... 14 Figure4. ..................................... 16 Figure5. ..................................... 18 Figure6. ..................................... 24 ADDITIONALSUMMARYOFFINDINGS . 25 DISCUSSION ..................................... 26 AUTHORS’CONCLUSIONS . 27 ACKNOWLEDGEMENTS . 27 REFERENCES ..................................... 28 CHARACTERISTICSOFSTUDIES . 40 DATAANDANALYSES. 130 Analysis 1.1. Comparison 1 NSAIDs vs placebo, Outcome 1 Pain relief dichotomous data. 136
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • Aspirin Suppresses the Growth and Metastasis of Osteosarcoma
    Published OnlineFirst July 22, 2015; DOI: 10.1158/1078-0432.CCR-15-0198 Cancer Therapy: Preclinical Clinical Cancer Research Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-kB Pathway Dan Liao, Li Zhong, Tingmei Duan, Ru-Hua Zhang, Xin Wang, Gang Wang, Kaishun Hu, Xiaobin Lv, and Tiebang Kang Abstract Purpose: Aspirin has recently been reported to reduce both t test or ANOVA with the Bonferroni post hoc test were used for the the incidence and the risk of metastasis in colon cancer. statistical comparisons. However, there is no evidence at the cellular levels or in the Results: Aspirin reduced cell viability in a dose- and time- animal models for such an effect of aspirin on cancer dependent manner in osteosarcoma cell lines, and aspirin syn- metastasis. ergistically sensitized osteosarcoma cells to cisplatin (DDP) Experimental Design: MTT assay, colony formation assay, and in vitro and in vivo (P < 0.001). Moreover, aspirin markedly apoptosis assay were employed to analyze the effects of aspirin on repressed the migration and invasion of osteosarcoma cells the osteosarcoma cell viability in vitro. The NF-kB activity was in vitro (P < 0.001), and dramatically diminished the occurrence measured by the NF-kB p65 luciferase reporter. Western blotting of osteosarcoma xenograft metastases to the lungs in vivo was used to analyze the proteins in cells. The migration and (P < 0.001). Mechanistically, aspirin diminishes osteosarcoma invasion abilities of osteosarcoma cells in vitro were measured migration, invasion, and metastasis through the NF-kB pathway. by the Transwell assay. Xenograft-bearing mice were used to assess Conclusion: Aspirin suppresses both the growth and metasta- the roles of aspirin in both tumor growth and metastasis of sis of osteosarcoma through the NF-kB pathway at the cellular osteosarcoma in vivo (n ¼ 5–8 mice/group).
    [Show full text]
  • Pengaruh Dexketoprofen Dengan Ketorolac Terhadap Kadar Kortisol Plasma Pada Tikus Wistar Yang Mengalami Insisi
    PENGARUH DEXKETOPROFEN DENGAN KETOROLAC TERHADAP KADAR KORTISOL PLASMA PADA TIKUS WISTAR YANG MENGALAMI INSISI JURNAL MEDIA MEDIKA MUDA Disusun untuk memenuhi sebagian persyaratan guna mencapai strata 1 Kedokteran Umum Disusun oleh: DEVINA ADIYANI PRANOWO 22010110110060 PROGRAM PENDIDIKAN SARJANA KEDOKTERAN FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO 2014 PENGARUH DEXKETOPROFEN DENGAN KETOROLAC TERHADAP KADAR KORTISOL PLASMA PADA TIKUS WISTAR YANG MENGALAMI INSISI DEVINA ADIYANI PRANOWO ABSTRAK Latar belakang: Luka pasca pembedahan seperti insisi dapat menimbulkan nyeri yang akan merangsang timbulnya respon stress metabolik (MSR) berupa peningkatan kadar kortisol. Meningkatnya kadar kortisol menyebabkan penekanan respon imun dan melambatnya penyembuhan luka. Pemberian Dexketoprofen dan Ketorolac akan mengurangi rasa nyeri yang berefek pada penurunan kadar kortisol dan mempercepat penyembuhan luka. Tujuan: Membuktikan adanya perbedaan pengaruh Dexketoprofen intramuskular dengan Ketorolac intramuskular terhadap kadar kortisol plasma pada tikus wistar yang mengalami insisi. Metode: Penelitian eksperimental dengan desain Randomize Post test only control group design. Penelitian menggunakan hewan coba tikus wistar sejumlah 10 ekor yang diambil dengan randomisasi yang memenuhi kriteria inklusi dan ekslusi. 10 ekor tikus wistar dibagi menjadi 2 kelompok masing- masing 5 ekor, Kelompok yang I (K I) akan diinsisi sepanjang 2cm dan diinjeksi Dexketoprofen intramuskular 0,225 mg setiap 6 jam selama 24 jam , Kelompk yang ke II (K II) akan diinsisi sepanjang 2cm dan diinjeksi Ketorolac intramuskular 0,54 mg setiap 6jam selama 24 jam. Pemeriksaan kadar Kortisol dilakukan 24 jam pasca insisi dengan sistem Immune Cortisol dan dibaca dengan perangkat ELISA reader. Hasil: Kadar kortisol plasma pada kelompok K I (Dexketoprofen) lebih rendah dibandingkan K II (Ketorolac) dan berdasarkan uji statistik didapatkan p = 0,006 yang berarti terdapat perbedaan yang bermakna ( p < 0,005) pada penurunan kadar kortisol plasma antara kelompok K I (Dexketoprofen) dengan K II (Ketorolac).
    [Show full text]
  • Dexketoprofen Pharmacare 25 Mg Film-Coated Tablets Dexketoprofen
    Package leaflet: Information for the patient Dexketoprofen Pharmacare 25 mg film-coated tablets Dexketoprofen Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dexketoprofen Pharmacare is and what it is used for 2. What you need to know before you take Dexketoprofen Pharmacare 3. How to take Dexketoprofen Pharmacare 4. Possible side effects 5. How to store Dexketoprofen Pharmacare 6. Contents of the pack and other information 1. What Dexketoprofen Pharmacare is and what it is used for Dexketoprofen Pharmacare is a pain killer from the group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It is used to treat mild to moderate pain, such as muscular pain, painful periods (dysmenorrhoea), toothache. 2. What you need to know before you take Dexketoprofen Pharmacare Do not take Dexketoprofen Pharmacare: If you are allergic to dexketoprofen or any of the other ingredients of this medicine (listed in section 6); If you are allergic to acetylsalicylic acid or to other non-steroidal anti-inflammatory medicines;
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]